- Home
- MAIA
as 07-08-2024 4:00pm EST
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CHICAGO |
| Market Cap: | 74.7M | IPO Year: | 2022 |
| Target Price: | N/A | AVG Volume (30 days): | 328.3K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.82 - $5.99 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of MAIA Biotechnology Inc. (MAIA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Louie Ngar Yee | MAIA | Director | Apr 25 '24 | Buy | $2.03 | 19,665 | $39,919.95 | 1,167,189 | SEC Form 4 |
| Smith Stan | MAIA | Director | Apr 25 '24 | Buy | $2.03 | 147,492 | $299,408.76 | 1,005,060 | SEC Form 4 |
| CHAOUKI STEVEN M | MAIA | Director | Mar 14 '24 | Buy | $1.17 | 34,641 | $40,529.97 | 88,891 | SEC Form 4 |
| Smith Stan | MAIA | Director | Mar 14 '24 | Buy | $1.17 | 170,940 | $199,999.80 | 857,568 | SEC Form 4 |
| Luput Cristian | MAIA | Director | Mar 14 '24 | Buy | $1.17 | 69,282 | $81,059.94 | 367,350 | SEC Form 4 |
Latest MAIA Biotechnology Inc. News
MAIA Breaking Stock News: Dive into MAIA Ticker-Specific Updates for Smart Investing
Business Wire
a month ago
MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA’s Approval of a Telomerase Inhibitor Agent Therapy
Business Wire
a month ago
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
Business Wire
a month ago
MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer
Business Wire
2 months ago
MAIA Biotechnology to Present at the BIO International Convention 2024
Business Wire
2 months ago
MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
Business Wire
2 months ago
MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement
Business Wire
2 months ago
MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement
Business Wire
3 months ago
MAIA Biotechnology Announces $1.00 Million Private Placement
Share on Social Networks:
Disclaimer
The information presented on this page, "MAIA MAIA Biotechnology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.